drugset / Trial / NCT00309621

Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis

NCT00309621

Phase 3 Completed 250 enrolled Basilea Pharmaceutica
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Patients with severe chronic hand dermatitis, that has not responded to topical treatment, including topical steroids and the avoidance of aggravating factors, will be treated with the oral medication alitretinoin. The study aims to investigate the safety and efficacy of the medication when given over a period of 6 months.

Timeline

Start
2006-04
Primary completion
2007-04
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject alitretinoin Other / unclassified 30 mg Oral

Indications